U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Wed Apr 02 02:04:14 GMT 2025
Edited
by admin
on Wed Apr 02 02:04:14 GMT 2025
Protein Sub Type
Sequence Type COMPLETE
Record UNII
9TTJ40KJ7S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RG-7103
Common Name English
R-7103
Preferred Name English
RO5024118
Code English
RO-5024118
Code English
L-THREONINAMIDE, N-ACETYL-L-HISTIDYL-L-SERYL-L-.ALPHA.-ASPARTYL-L-ALANYL-2-METHYL-L-VALYL-L-PHENYLALANYL-L-THREONYL-L-.ALPHA.-GLUTAMYL-L-ASPARAGINYL-L-TYROSYL-L-THREONYL-L-LYSYL-L-LEUCYL-L-ARGINYL-L-LYSYL-L-GLUTAMINYL-L-NORLEUCYL-L-ALANYL-L-ALANYL-L-LYSY
Systematic Name English
Code System Code Type Description
CAS
1001080-55-2
Created by admin on Wed Apr 02 02:04:14 GMT 2025 , Edited by admin on Wed Apr 02 02:04:14 GMT 2025
PRIMARY
PUBCHEM
90871060
Created by admin on Wed Apr 02 02:04:14 GMT 2025 , Edited by admin on Wed Apr 02 02:04:14 GMT 2025
PRIMARY
SMS_ID
100000175613
Created by admin on Wed Apr 02 02:04:14 GMT 2025 , Edited by admin on Wed Apr 02 02:04:14 GMT 2025
PRIMARY
FDA UNII
9TTJ40KJ7S
Created by admin on Wed Apr 02 02:04:14 GMT 2025 , Edited by admin on Wed Apr 02 02:04:14 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY
RO5024118 demonstrated increased stability to neutrophil elastase compared with RO0251553. In human and guinea pig isolated airway preparations, RO5024118 induced bronchodilatory effects comparable with RO0251553 and the long-acting .BETA.-agonist salmeterol and was significantly more potent than native vasoactive intestinal peptide and the short-acting .BETA.-agonist salbutamol. In 5-HT-induced bronchoconstriction in guinea pigs, RO5024118 exhibited inhibitory activity with similar efficacy as, and longer duration than, RO0251553. In a lipopolysaccharide-mouse model, RO5024118 inhibited neutrophil and CD8(+) cells and myeloperoxidase levels. In rats, intratracheal instillation of PPE induced airway neutrophilia that was resistant to dexamethasone. Pretreatment with RO5024118 significantly inhibited PPE-induced neutrophil accumulation. These results demonstrate that RO5024118 induces dual bronchodilatory and pulmonary anti-inflammatory activity and may be beneficial in treating airway obstructive and inflammatory diseases.
ACTIVE MOIETY
Status: Withdrawn; Protocol number: NP22131; Sponsor: Hoffmann-La Roche; Brief summary: This study will assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of RO5024118 following repeated inhalation in patients with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD). Patients will be randomized to receive multiple inhaled doses of R7103, as compared with placebo. The target sample size is approximately 30 individuals. Target sample size is 12.
ACTIVE MOIETY
Originator: Roche; Class: Antiasthmatic, Small molecule; Mechanism of Action: Vasoactive intestinal peptide type II receptor agonist; Highest Development Phase: Discontinued for Chronic obstructive pulmonary disease; Most Recent Event: 27 Oct 2009 Phase-I development is ongoing

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID SUBSTITUTION [1_1] HISTIDINE Amount: N-ACETYLHISTIDINE K9T7JPU4ML
AMINO ACID SUBSTITUTION [1_17] Amount: NORLEUCINE 832C8OV84S
AMINO ACID SUBSTITUTION [1_31] THREONINE Amount: THREONINAMIDE G5H9PK5HEK
AMINO_ACID_SUBSTITUTION [1_21] [1_25] SITE_SPECIFIC LYS-ASP LACTAM U3R4W875S0
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER AVERAGE(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL